Advance Search

Survivability Rates Based on Molecular Subtype, Stage and Metastasis of 36 months cohort in Breast Cancer Patients

DOI: https://doi.org/10.20956/nmsj.v7i1.20092
Article History

Submited : February 21, 2022
Published : April 16, 2022

Introduction:  Breast cancer treatment is carried out at the early stage of the disease, and a comprehensive assessment of the subtype, stage, and incidence of metastases is required. This study aims to determine breast cancer patients' overall survival (OS) and disease-free survival (DFS) based on subtype, stage, and incidence of metastases. Methods:  An observational analytic study with a retrospective cohort design was performed on eligible breast cancer patients at Wahidin Sudirohusodo Hospital from 2016 to 2019. Univariate analysis, and the Kaplan-Meier survival log-rank method (Mantel-Cox), were used to determine differences in survivability rates (OS and DFS) based on subtype, stage, and incidence of metastases. Results:   A total of 172 breast cancer patients from 32 years to 84 years with a mean age of 53.5 years. The most subtypes were Luminal A (34.9%) patients, and the least was Luminal B (15.7%) patients. A total of 85 (49.4%) patients survived during these three years, while 87 (50.6%) died. Based on the results of statistical tests in this study, there were no significant differences between the subtypes with DFS and OS, but on the contrary, there was a significant difference between the stage and incidence of metastases with OS and DFS (p<0.05). Conclusions:  There were no statistically significant differences between the subtypes with OS and DFS. This study showed a significant difference between the stage and incidence of metastases with OS and DFS

References

  1. Ghoncheh M, Mahdavifar N, Darvishi E, Salehiniya H. Epidemiology, Incidence and Mortality of Breast Cancer in Asia. Asian Pac J Cancer Prev. 2016;17(sup3):47-52. doi:10.7314/APJCP.2016.17.S3.47
  2. The International Agency for Research onCancer (IARC). Global Cancer Observatory. Accessed February 20, 2022. https://gco.iarc.fr/
  3. Health Department of South Sulawesi Province. 2014 Non-Communicable Disease Case Report. Published online 2014.
  4. Nguyen D, Yu J, Reinhold WC, Yang SX. Association of Independent Prognostic Factors and Treatment Modality With Survival and Recurrence Outcomes in Breast Cancer. JAMA Netw Open. 2020;3(7):e207213. doi:10.1001/jamanetworkopen.2020.7213
  5. Ginsburg O, Yip CH, Brooks A, et al. Breast cancer early detection: A phased approach to implementation. Cancer. 2020;126(S10):2379-2393. doi:10.1002/cncr.32887
  6. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412-424. doi:10.5306/wjco.v5.i3.412
  7. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(9):2206-2223. doi:10.1093/annonc/mdt303
  8. Arnone P, Zurrida S, Viale G, et al. The TNM classification of breast cancer: need for change. Updat Surg. 2010;62(2):75-81. doi:10.1007/s13304-010-0014-y
  9. Kimbung S, Loman N, Hedenfalk I. Clinical and molecular complexity of breast cancer metastases. Semin Cancer Biol. 2015;35:85-95. doi:10.1016/j.semcancer.2015.08.009
  10. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ. 2000;321(7261):624-628. doi:10.1136/bmj.321.7261.624
  11. Su Y, Zheng Y, Zheng W, et al. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer. 2011;11:292. doi:10.1186/1471-2407-11-292
  12. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic Behavior of Breast Cancer Subtypes. J Clin Oncol. 2010;28(20):3271-3277. doi:10.1200/JCO.2009.25.9820
  13. Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. 2019;19(1):1091. doi:10.1186/s12885-019-6311-z
  14. Simon SD, Bines J, Werutsky G, et al. Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study. Breast Edinb Scotl. 2019;44:113-119. doi:10.1016/j.breast.2019.01.008
  15. Zegarac M, Nikolic S, Gavrilovic D, et al. Prognostic factors for longer disease free survival and overall survival after surgical resection of isolated liver metastasis from breast cancer. J BUON Off J Balk Union Oncol. 2013;18(4):859-865.
Wijayanto, A., Pieter, J. S. L. A., Prihantono, P., Syamsu, S. A., Thaufix, N. S., & Abdi, A. (2022). Survivability Rates Based on Molecular Subtype, Stage and Metastasis of 36 months cohort in Breast Cancer Patients. Nusantara Medical Science Journal, 7(1), 29-38. https://doi.org/10.20956/nmsj.v7i1.20092

Copyright (c) 2022 Array

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Downloads

Download data is not yet available.
Fulltext
PDF